As expected, the European Commission approves Bristol-Myers Squibb’s (NYSE:BMY) Empliciti (elotuzumab), combined with Celgene’s Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received at least two prior lines of therapy, including Celgene’s REVLIMID (lenalidomide) and a proteosome inhibitor and have progressed on the last therapy.
The advisory group CHMP adopted a positive opinion backing approval a month ago.
Empliciti was first approved in the EU (combined with lenalidomide and dexamethasone) for adults with MM who have received at least one prior line of therapy.
Related ticker: AbbVie (NYSE:ABBV)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.